= Emerging. More than 5 years before clinical availability. (26.62%)
= Expected to be clinically available in 1 to 4 years. (38.91%)
= Clinically available now. (34.47%)
MSACL 2020 US : Margulis

MSACL 2020 US Abstract

Topic: Imaging

Podium Presentation in Room 4 on Thursday at 11:00 (Chair: David Muddiman)

Metabolic Profiling of MYC-induced Tumors by DESI-MSI to Identify Possible Druggable Targets

Katy Margulis (Presenter)
The Hebrew University of Jerusalem

Presenter Bio(s): I hold a bachelor degree in Pharmacy from the Hebrew University of Jerusalem, Israel. I did my PhD at the same university specializing in nanocscience and drug delivery with Prof. Shlomo Magdassi (Chemistry Department). During my postdoctoral training with Prof. Richard Zare at Stanford University, USA I worked on ambient mass spectrometry imaging of clinical specimens, mostly employing Desorption Electrospray Ionization Mass Spectrometry Imaging (DESI-MSI).
I started a tenure track position as a Senior Lecturer (Assistant Professor) at the School of Pharmacy, the Faculty of Medicine, the Hebrew University of Jerusalem, Israel, in September 2019.

Authors: Katy Margulis (1,2), Arvin Gouw (1), Natalie Liu (1), Richard N. Zare (1), Dean W. Felsher (1)
(1) Stanford University, CA (2) Hebrew University of Jerusalem, Jerusalem, Israel

Abstract

Introduction

Cancers have altered metabolism, and its investigation may uncover unique therapeutic vulnerabilities. The MYC proto-oncogene is frequently mutated and overexpressed in human cancers, but its role in metabolic changes involved in initiation, maintenance, and progression of tumors remains vague. Experimentally, MYC inactivation regresses tumors however, therapies that target MYC directly have yet to be identified.

Methods

In collaboration with the Oncology Department, Stanford School of Medicine, we monitored MYC-induced tumorigenesis in four conditional transgenic mouse models: kidney, liver, lung and leukaemia tumors. In these models MYC overexpression could be activated on demand to induce tumorigenesis, and later could be blocked fully regressing the tumors. These models present excellent systems to study metabolic hallmarks of tumor generation, maintenance and regression. We employed Desorption Electrospray Ionization Mass Spectrometry Imaging (DESI-MSI) to reveal their unique metabolic derangements and to identify and validate possible druggable targets. We also examined MYC-driven cell-lines and human xenograft models.

Results

We have uncovered a mutual signature for all studied MYC-driven cancers and possible druggable targets in their metabolism. Thus, we have determined that MYC closely cooperates with the transcription factor Sterol Regulated Element-Binding Protein (SREBP1) and together they activate fatty acid (FA) synthesis, and drive FA chain elongation. We identified acetyl-CoA carboxylase A (ACACA) as one of the enzymes overactivated by this cooperation, which also presents a potential druggable target. We specifically inhibited this enzyme and monitored the therapeutic efficacy of this inhibition by DESI-MSI. This inhibition diminished MYC induced tumorigenesis, elicited the regression of established tumors, and prevented tumor formation. We also found that sensitivity to this inhibition is somewhat specific to MYC-driven tumors. Finally using DESI-MSI we could track the shift in metabolic products which occurred as the result of ACACA inhibition. In addition, by DESI-MSI we found that across different tumors MYC induction specifically increased the abundances of glycerophosphoglycerol species. Upon MYC inactivation, glycerophosphoglycerol abundances returned to basal level. Guided by DESI-MS results, we performed gene expression analysis and found that MYC causally induces genes across the biosynthetic pathway toward glycerophosphoglycerol formation. Transcription of at least seven of the genes was induced, and hence any of their corresponding enzyme could present a facile druggable target.

Conclusions & Discussion

This study proves that mapping tumors by DESI-MSI can not only delineate the tumors from normal tissue, but also shed light on mechanistic pathways of tumorigenesis and identify potential druggable targets. These results were recently published in Cell Metabolism.


Financial Disclosure

DescriptionY/NSource
Grantsno
Salaryno
Board Memberno
Stockno
Expensesno
IP Royaltyno

Planning to mention or discuss specific products or technology of the company(ies) listed above:

no